HF
ANVS icon

HRT Financial’s Annovis Bio ANVS Stock Holding History

HRT Financial’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47K Buy
+21,187
New +$58.1K ﹤0.01% 3463
2025
Q4 		– Sell
-37,579
Closed -$77K – 3131
2025
Q3 		$77K Buy
37,579
+27,074
+258% +$67.7K ﹤0.01% 2551
2025
Q2 		$22K Buy
+10,505
New +$20.7K ﹤0.01% 2389

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

HRT Financial's ANVS Position: Q1 2026 in Review

HRT Financial opened a new position in Annovis Bio (ANVS) in Q1 2026: 21,187 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #3463 among its holdings. This is a return to the name: HRT Financial previously reported a position in ANVS as recently as Q3 2025.

HRT Financial first reported a position in ANVS in Q2 2025 and has held it in 3 quarters since. The position peaked at $77K in Q3 2025. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • HRT Financial held 21,187 shares of Annovis Bio worth $47K as of Q1 2026.
  • Annovis Bio was a new HRT Financial position in Q1 2026.
  • Annovis Bio made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3463 holding.
  • HRT Financial first reported a position in Annovis Bio in Q2 2025 and has held it in 3 quarters since.
  • HRT Financial's Annovis Bio position peaked at $77K in Q3 2025.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.